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Summary We measured serum concentrations of hapatocyte growth factor (HGF) in patients with gastric cancer and compared these with
the histological findings and conventional tumour markers, including CEA, CA19-9 and CA125, for evaluation of the significance of serum
HGF levels as a tumour marker. The HGF levels were measured by an enzyme-linked immunosorbent assay (ELISA) system. The average
levels of serum HGF in 89 healthy control subjects, 104 patients with primary gastric cancer and 15 patients with recurrent gastric cancer
were 0.31 ± 0.11 ng ml-1, 0.42 ± 0.50 ng ml-1 and 0.92 ± 0.39 ng mi-1 respectively. The average level in patients with recurrent disease was
significantly higher than in healthy control subjects and in primary cancer patients (P< 0.001 and P< 0.003 respectively). Of 104 patients with
primary gastric cancer, 35 (33.7%) showed an aberrant increase in the circulating level of HGF. The increased HGF levels were significantly
associated with the degrees of histological tumour invasion and venous invasion. Of 15 patients with recurrent gastric cancer, 14 (93.3%)
showed an aberrant increase. No correlation was found between serum HGF levels and CEA levels, CA19-9 levels and CA125 levels.
However, the rate of the aberrant increase in HGF levels was significantly higher than that of any other tumour markers, including CEA,
CAl 9-9 and CAl25, in primary gastric cancer patients. In conclusion, the circulating levels of HGF were elevated in approximately one-third
of patients with primary gastric cancer, particularly in those with high grades of histological tumour invasion and venous invasion, and
frequently in patients with distant metastases, suggesting that HGF might play important roles in the tumour progression of gastric cancer.
Furthermore, serum HGF levels may be of value as a tumour marker in patients with gastric cancer.
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Hepatocyte growth factor (HGF) was first identified as a molecule
that stimulates hepatocyte proliferation (Nakamura et al, 1984).
Later, it was known to be a multifunctional molecule for various
types of cells, including endothelial cells and tumour cells.
Particularly important biological activities ofHGF in tumour cells
are the ability to increase cell motility (Tajima et al, 1992) and to
modulate angiogenesis (Rosen et al, 1990; Grant et al, 1993) as
these are strongly associated with tumour invasion and the devel-
opment of distant metastases. In recent clinical investigations, it
was documented that HGF is apotent and independent predictorof
recurrence and survival in primary breast cancer patients
(Yamashita et al, 1994). In addition, we have shown that serum
HGF levels are frequently elevated in patients with recurrent
breast cancer, in particular those with liver metastases (Taniguchi
et al, 1995). These findings indicate that elevation of circulating
HGF is involved in the systemic progression ofbreast cancer.
In the gastrointestinal tract, HGF modulates intestinal epithelial
cell proliferation and migration (Dignass et al, 1994). It has been
shown that c-Met, an HGF receptor, is frequently overexpressed in
human gastric cancer cells and cancer tissues (Di Renzo et al, 1991).
Kuniyasu et al (1993) have demonstrated that 23% ofprimary gastric
tumours show amplification of the c-met gene. Thus, we measured
serum concentrations of HGF in patients with gastric cancer and
compared them with the histological findings and conventional
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tumourmarkers,including CEA,CA19-9 andCA125,forevaluation
ofthe significance ofserum HGF levels as a tumour marker.
PATIENTS AND METHODS
Patients and healthy control subjects
One hundred and four patients with primary gastric cancer and 15
withrecurrentdisease,treated attheTokyoMetropolitan Komagome
Hospital from 1991 to 1994,were enrolled in this study.The average
age ofthe patients with primary gastric cancer was 64.0 years (range
31-88 years), including 74 men and 30 women. Patients with
primary gastric cancerconsisted of28 stage Ipatients, 17 stage11, 25
stage III and 34 stage IV, according to the General Rules for the
Gastric Cancer Society, 12th edition, (which is based on the UICC
criteria) by theJapaneseResearch SocietyforGastric Cancer.The 15
patients with recurrent gastric cancer included six with liver metas-
tases andnine without livermetastases,ofwhomeighthadperitoneal
recurrence and one had distant lymph node metastases. Liver and
distant lymph node metastases were diagnosed by computerized
tomographic (CT) scan. Patients with liver dysfunction due to
hepatitis B andC virus infection andfatty degradation wereexcluded
from this study. Eighty-nine healthy volunteers without any liver
dysfunction, including 47 men and 42 women, were also enrolled in
this study. Their average age was 49.7 years (range 40-59 years).
Samples
Venous blood samples were drawn into a tube and centrifuged at
3000 r.p.m. for 10 min, and the samples were stored at -20°C until
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Figure 1 Standard curve for HGF determined by ELISA. Recombinant
human-HGF at 0.1, 0.3, 1.0 and 3.0 ng ml-' were incubated with anti-HGF
monoclonal antibody
used for determination ofHGF. Primary tumours were resected and
fixed with formalin.
Preparation of monoclonal antibody to human HGF
Monoclonal antibody (MAb) against human hepatocyte growth
factor (hHGF) was prepared according to the conventional proce-
dure of Fuller et al (1987). BALB/c mice were immunized subcu-
taneously with 30 jg hHGF in Freund's incomplete adjuvant. Mice
were booster injected once with 10 jg hHGF in Freund's incom-
plete adjuvant. The mice were killed 3 days after the last immu-
nization, and spleen cells were fused with NS-1 mouse myeloma
cells using polyethylene glycol. To prepare MAb, established
hybridoma cells were injected intraperitoneally into BALB/c and
the MAbs were purified on a protein A-Sepharose column.
Enzyme-linked immunoassay
The level of HGF in sera was determined using an HGF-ELISA
kit (Institute of Immunology, Tokyo, Japan). A specific sandwich
method with a mouse monoclonal antibody to recombinant human
hepatocyte growth factor (anti-HGF-a chain antibody) and mouse
monoclonal antibodies labelled by peroxidase was used in this
ELISA system. Twofold diluted sera were used for the measure-
ment of HGF (Yamada et al, 1995). The standard curve of HGF
showed absorbance linearity from 0.10 to 6.4 ng m1' (Figure 1).
The limit ofdetection in this kit is 0.10 ng ml-'.
Measurement of CEA, CA19-9 and CA125 in sera
The levels ofCEA, CA19-9 and CA125 in the same serum sample
were examined using the ELISA system. The cut-off levels
for CEA, CA19-9 and CA125 were 6.2 ng mP, 58.0 U ml-l and
35.0 U ml' respectively.
Histological diagnosis
Thin sections ofabout 5 jim thickness were cut from surgical large
sections with a microtome. These were mounted on large glass
slides and stained with haematoxylin-eosin and elastica van
Gieson. Venous invasion was defined when tumour cells filled the
vein and appeared to adhere to the vein wall. When tumour cells
were situated in a lumen surrounded by endothelial cells without
elastic fibres or smooth muscle, this was classified as lymphatic
invasion. The histological type was classified as eithera differenti-
ated type (so called expanding or well-differentiated type) or an
undifferentiated type (so-called infiltrating orpoorly differentiated
type) (Ming, 1977). All tissue specimens were examined by
pathologists.
Statistical analysis
The Student's t-test was used for analyses of unpaired samples,
and the paired t-test was used when samples were paired. The chi-
squared test was also used to test the significance between two
groups. Correlation was assessed using Spearman's correlation
coefficiency by rank.
Table 1 Serum HGF levels and characteristics of healthy controls and patients with primary gastric cancer
Healthy control subjects Gastric cancer patients
No. Average Range of values No. Average Range of values
of ± s.d. P-value (ng ml-') of ± s.d. P-value (ng ml-1)
cases (ng ml-1) cases (ng ml-')
Sex
Male 47 0.30±0.10 0.14-0.42 74 0.49±0.57 0.10-4.06
NS 1 0.03
Female 42 0.32+0.12 0.15-0.69 30 0.24±0.18 0.11-0.65
Age (years)
> 60 89 0.31 ± 0.11 0.14-0.69 37 0.35±0.27 0.11-1.17
NS
<60 - - - 67 0.45 ± 0.59 0.10-4.06
Statistical analysis demonstrates a significant difference in serum HGF levels between male patients and female patients (P< 0.03). s.d. Standard deviation;
NS, not significant.
British Journal ofCancer (1997) 75(5), 673-677
. . . . *1* . * * . * I
0 CancerResearch Campaign 1997Hepatocyte growth factorin gastric cancer 675
Table 2 Serum HGF levels and clinical stage in 104 patients with primary
gastric cancer
No. Average
of ± s.d. P-value Range of value
cases (ng ml-') (ng ml-1)
Stage
28 0.27 ± 0.19 - 0.10-0.80
11 17 0.39 ± 0.34 0.11-1.12
<0.05
III 25 0.54 ± 0.59 0.14-4.06
IV 34 0.46 ± 0.23 1 0.27-2.78
There is a significant difference in serum HGF level between stage patients
and stage IV patients (P< 0.05). s.d. Standard deviation; NS, not significant.
RESULTS
The average levels of HGF in the sera of 89 healthy control
subjects and patients with primary gastric cancer were 0.31 ± 0.11
(average ± s.d.) ng ml-1 and 0.42 ± 0.50 ng ml-l respectively
(P =0.054) (Table 1). The average level formale patients was 0.49
± 0.57 ng ml-' and for female patients was 0.24 ± 0.18 ng ml-1
(male vs female, P < 0.03). The highest HGF level recorded in
the patients was 4.055 ng ml-'. Sixteen (18.0%) of 89 healthy
control subjects and 35 (33.7%) of 104 patients had on HGF level
ofover0.4 ng ml-' in the serum. Serum HGF levels in stage III and
stage IV patients were higher than 0.4 ng ml-', and a statistically
significant difference was found between those of stage I patients
and those of stage IV patients (P < 0.05 by t-test) (Table 2).
Histological factor analyses demonstrated that the serum HGF
level was significantly correlated with tumour invasion (t) and
intratumoral venous invasion grade (v) (tl vs t4, P < 0.02 and vO,
vl, v2 vs v3, P <0.003 by t-test; Table 3). In contrast, there was no
significant correlation between serum HGF levels and the degrees
of paragastric lymph node metastases and that of intratumoral
lymphatic invasion. There was also no significant difference
between serum HGF levels of differentiated type and those of
undifferentiated type (Table 3).
In comparison with conventional tumour markers for gastric
cancer, serum HGF levels were elevated in 69 (33.7%) of 104
patients with primary gastric cancer. Serum CEA levels, serum
CAl9-9 levels and serum CA125 levels were elevated in 21
(20.2%), 14 (13.5%) and 15 (14.4%) cases respectively. There
were statistically significant differences between HGF levels and
CAl9-9 levels in stage II (P < 0.04) and in stage III (P < 0.04)
patients. Also, there were significant differences between HGF
Table 3 Serum HGF levels and pathological findings in 104 patients with
primary gastric cancer
No. Average Range of Postive
of ± s.d. P.value values rate (%)
cases (ng ml-') (ng ml-') (. 0.4
ng ml-')
1 25 0.29±0.24 - 0.10-1.12 17.4
2 24 0.36± 0.27 0.13-1.06 39.1
<0.02
3 47 0.46 ± 0.59 < 0.04 0.12-4.06 37.0
4 8 0.79 ± 0.85 - 0.27-2.78 50.0
n
- 33 0.32 ± 0.28 0.10-1.12 26.6
NS
+ 71 0.48 ± 0.58 0.12-4.06 38.8
ly
0 14 0.27 ± 0.18 0.10-0.64 23.1
1 24 0.38 ± 0.59 0.12-2.78 18.2
NS
2 34 0.40±0.25 0.15-1.17 40.6
3 32 0.54 ± 0.70 0.20-4.06 41.9
v
0 16 0.26 ± 0.16 0.10-0.64 13.3
1 22 0.35 ± 0.27 _ 0.14-1.06 33.3
2 40 0.35 +0.20 < 0.003 0.12-0.83 36.8
3 26 0.70 ± 0.92 1 0.20-4.06 41.7
Differentiated 44 0.45 ± 0.64 0.11-4.06 34.1
NS
Undifferentiated 60 0.41 ± 0.16 0.10-2.78 36.7
The increase in the level of HGF is significantly associated with the status of
microscopical tumor invasion and with the grade of histological venous
invasion. (The t, v and ly mean histological evidence oftumour invasion,
vascular invasion and lymphatic invasion in the tumour respectively.) s.d.
Standard deviation; NS, not significant.
levels and CA125 levels in stage II (P < 0.04) and in stage III
patients (Table 4). No significant correlation was seen between
serum HGF levels and serum CEA levels, CA19-9 levels and
CA125 levels (data not shown).
Of 15 patients with recurrent gastric cancer, 14 (93.3%) exhib-
ited HGF levels > 0.4 ng ml,-1 in the serum. The mean value of
serum HGF levels in patients with recurrent gastric cancer was
0.92 ± 0.39 ng ml-' and a significant difference was found when
compared with HGF levels in healthy controls and in patients with
primary gastric cancer (P < 0.0001 and P < 0.003 respectively)
(Figure 1). Patients with primary gastric cancer had higher levels
Table 4 Differentiation with serum HGF levels and conventional tumour markers
No. Per cent with Per cent with Per cent with Per cent with
of elevated elevated elevated elvated
cases HGF levels CEA levels P CA19-9 levels P* CA125 levels P**
Stage
28 17.9 7.1 NS 3.6 NS 10.7 NS
11 17 37.5 23.5 NS 5.9 < 0.04 5.9 < 0.04
III 25 44.0 20.0 NS 8.0 < 0.04 16.0 < 0.04
IV 34 38.2 29.4 NS 29.4 NS 20.6 NS
There was no significant correlation between serum HGF levels and conventional tumour markers (data not shown). *P, HGF vs CEA; **P, HGF vsCAl 9-9;
***P, HGF vsCA125. NS, not significant.
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Figure 2 The circulating level of HGF in healthy control subjects (n = 89), in
patients with primary gastric cancer (n = 104) and in patients with recurrent
disease (n = 15). *P= 0.054, **P> 0.001, *** P > 0.003
of serum HGF than healthy control subjects but there was no
significant difference between the two groups (P = 0.054). No
significant difference was found between recurrent patients with
liver metastases (n = 6) and those without liver metastases (n = 9).
DISCUSSION
In this study, we found an aberrant increase in serum HGF levels in
patients with gastric cancer. Male patients had apparently higher
circulating levels of HGF than female patients because of the
different proportions in clinical stage between male patients and
female patients (data not shown). In patients with primary gastric
cancer, there was a significant correlation between the elevation of
serum HGF levels and the high degree ofhistological tumour inva-
sion and venous invasion, whereas we could find no significant
correlation between HGF levels and degrees of histological nodal
metastases (n) and lymphatic invasion (ly). Furthermore, the
average circulating level of HGF in patients with recurrent gastric
cancer was significantly higher than that in healthy controls (P <
0.001) and in patients with primary disease (P < 0.003). The
average level in patients with primary gastric cancer was apparently
higherthan that in healthy control subjects (P =0.054). We have not
studied whether the circulating level of HGF in patients with
primary gastric cancer would decrease aftergastrectomy. The circu-
lating level of patients with breast cancer was significantly
decreased after mastectomy (Taniguchi et al, 1995) and pleural
effusion samples, which were obtained from patients with lung
cancer and various types ofmalignantdisease, contained high levels
of HGF (Eagles et al, 1996). These observations strongly suggest
that increased circulating levels of HGF are related to progression
of various types of malignant tumour, including gastric cancer. In
fact, it was documented that 55% ofgastric carcinoma cell lines and
23% of advanced gastric carcinomas show c-met gene amplifica-
tion; the c-met gene was expressed in all of the tissue samples not
only from gastric carcinoma tissue but also from normal stomach
mucosa (Kuniyasu et al, 1993). Immunohistochemically, HGF was
also identified from fibroblasts on the gastric wall. Furthermore, a
recent study noted that Helicobactorpylori, which induces hyper-
proliferation of the gastric mucosa, stimulates the expression of
HGF in human gastric mucosa (Kondo et al, 1995). Thus, there are
many experimental and clinical data that indicate that HGF might
play an importantrole in tumourdevelopmentandgrowthofhuman
gastric cancer.
HGF is secreted as a single-chain biologically inactive
precursor (pro-HGF), mostly found in a matrix-associated form
(Naka et al, 1992; Naldini et al, 1992). In vitro, this pro-HGF
is converted to the active mature HGF heterodimer by pure
urokinases (Naldini et al, 1995) which are the most commonly
expressed proteases in solid tumours, including stomach cancer. In
addition, the prognostic value of urokinases has been noted in
various types of tumours (Foekens et al 1995; Hildenbrand et al,
1995). Several cytokines and growth factors, including interleukin
1a and 1 and tumour necrosis factor-a from stromal cells can
modulate the production and secretion of hHGF (Tamura et al,
1993). On the other hand, transforming growth factor -, is known
to be primarily responsible for mediating the down-regulation of
HGF production in fibroblasts (Seslar et al, 1995). Such interac-
tions between epithelial cells and mesenchymal cells are thought
to be crucial forthe regulation ofHGF activities in cancer invasion
and metastasis. Recently, we found a marked induction of serum
HGFby heparin (Taniguchi et al, 1994). Therefore, heparin activi-
ties, which are also noted toregulate stromal cells through the acti-
vation of proteases, seem to be important for the regulation of
HGF in serum. For breast cancer patients, we have also found an
increase in the circulating level ofHGF. Also in breast cancer, the
aberrant increase in HGF was significantly associated with the
number of axial lymph node metastases and the venous invasion
grade (Taniguchi et al, 1995), suggesting that the induction of
HGF in sera associated with tumour progression may be a general
event in various types of human tumours. Although we have not
examined intratumoral HGF concentrations in gastric cancer
tissues, some mediators, such as injurin, may be involved in the
elevation ofHGF in the serum.
There was no significant correlation between HGF and other
conventional tumour markers in 104 patients with primary gastric
cancer. The positive rate ofHGF elevation was higher than that of
any other tumour marker, including CEA, CA19-9 and CA125, in
every clinical stage. Particularly in patients with stage II or stage
III gastric cancer, there was a significant difference between HGF
CAl9-9 and CA125. Recently, various tumour markers for gastric
cancer were reported from many clinical institutes, including
CA72-4, TPA and CA50 (Guadagni et al, 1992; Wobbes et al,
1992). However, after a review of the literature, the measurement
of serum HGF levels seems to be the most sensitive method for
monitoring tumour progression in gastric cancer. Furthermore, the
elevation of HGF seems to affect the biological activities of
tumour cells in the same way as an endocrine growth factor. We
consider that serum HGF level may be a promising tumour marker
in patients with gastric cancer.
In conclusion, the aberrant increase in serum HGF levels seems
to be associated with tumour progression in gastric cancer,
suggesting that the suppression of HGF activities may be of value
as a treatment for patients with gastric cancer.
ABBREVIATIONS
HGF, hepatocyte growth factor; CEA, carcinoembryonic antigen
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